Pegloticase - Horizon Pharma

Drug Profile

Pegloticase - Horizon Pharma

Alternative Names: KRYSTEXXA; Methoxypolyethylene glycol uricase; PEG urate oxidase; PEG-uricase; PEGylated uricase; Polyethylene glycol-uricase; Puricase; Urate-oxidase-PEG

Latest Information Update: 08 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke University; Mountain View Pharmaceuticals
  • Developer Horizon Pharma Rheumatology; Savient Pharmaceuticals
  • Class Antigouts; Oxidoreductases; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Urate oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gout
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout

Most Recent Events

  • 26 Sep 2018 Phase-II clinical trials in Gout (Combination therapy) in USA (IV) (NCT03635957)
  • 08 Aug 2018 Horizon Pharma plans the phase II MIRROR trial for Gout (In combination with methotrexate) in September 2018 (NCT03635957)
  • 15 Jun 2018 Updated efficacy data from phase III trials in Gout released by Horizon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top